QTTB Q32 Bio Inc.

Nasdaq www.q32bio.com


$ 3.90 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 05:03:29 EDT
QQQ $ 603.36 $ 0.00 (0 %)
DIA $ 464.56 $ 0.00 (0 %)
SPY $ 666.37 $ 0.00 (0 %)
TLT $ 91.01 $ 0.00 (0 %)
GLD $ 387.11 $ 0.00 (0 %)
$ 3.87
$ 3.93
$ 3.63 x 100
$ 4.00 x 5
-- - --
$ 1.35 - $ 53.17
695,665
na
47.2M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.29) by 39...

 why-levi-strauss-shares-are-trading-higher-by-8-here-are-20-stocks-moving-premarket

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers...

Core News & Articles

Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapi...

Core News & Articles

Wells Fargo analyst Derek Archila maintains Q32 Bio (NASDAQ:QTTB) with a Equal-Weight and lowers the price target from $16 t...

Core News & Articles

Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.51) by 23...

Core News & Articles

Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and co...

Core News & Articles

-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evalua...

Core News & Articles

BMO Capital analyst Etzer Darout downgrades Q32 Bio (NASDAQ:QTTB) from Outperform to Market Perform and lowers the price tar...

Core News & Articles

Piper Sandler analyst Christopher Raymond downgrades Q32 Bio (NASDAQ:QTTB) from Overweight to Neutral and lowers the price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION